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Carnitine palmitoyltransferase 1Heart failure is a major cause of morbidity and mortality in the world. Cardiac energy metabolism, speciﬁcally
fatty acid and glucose metabolism, is altered in heart failure and has been implicated as a contributing factor
in the impaired heart function observed in heart failure patients. There is emerging evidence demonstrating
that correcting these changes in energy metabolism by modulating mitochondrial oxidative metabolism may
be an effective treatment for heart failure. Promising strategies include the downregulation of fatty acid ox-
idation and an increased coupling of glycolysis to glucose oxidation. Carnitine palmitoyl transferase I (CPT1),
fatty acid β-oxidation enzymes, and pyruvate dehydrogenase kinase (PDK) are examples of metabolic targets
for the treatment of heart failure. While targeting mitochondrial oxidative metabolism is a promising strategy
to treat heart failure, further studies are needed to conﬁrm the potential beneﬁcial effect of modulating these
metabolic targets as an approach to treating heart failure. This article is part of a Special Issue entitled:
Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Heart failure has become themost common cause of mortality in de-
veloped countries [1]. Heart failuremost commonly is the result of either
cardiac ischemia, cardiac hypertrophy, or is due to idiopathic origins
[2,3]. Heart failure is characterized by a progressive decline in the ability
of the heart to ﬁll with and eject adequate amounts of blood to meet the
requirements of the body [4,5]. The heart has a high energetic demand
[6,7]. In pathological conditions such as heart failure and ischemic
heart disease, the altered regulation of cardiac fatty acid and glucose
metabolism is believed to contribute to impaired heart efﬁciency and
function. There is evidence that therapeutically regulating cardiac me-
tabolism by reducing fatty acid oxidation and/or increasing glucose oxi-
dation can improve the function of the failing heart. This paper will
review cardiac energy metabolism, metabolism of the failing heart, and
the potential of metabolic targets for the treatment heart failure.
2. Cardiac metabolism
2.1. Glucose metabolism
The heart utilizes many substrates for energy metabolism, including
glucose and fatty acids. Glucose uptake in cardiacmuscle is regulated by
the translocation of the glucose transporters GLUT1 and GLUT4 to theyocyte Biology: Cardiac Path-
ch Center, University of Alberta,
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rights reserved.cell membrane [8]. The intracellular glucose is sequestered inside the
cell by being phosphorylated to glucose-6-phosphate by either hexoki-
nase I or II. In the adult cardiomyocyte the dominant isoforms are
GLUT4 and hexokinase II while in the fetal heart the dominant isoforms
are GLUT1 and hexokinase I [9,10]. Intracellular glucose can either be
stored as glycogen or can enter the glycolytic pathway (Fig. 1).
Phosphofructokinase 1 (PFK1) is the step in glycolysis at which glucose
becomes completely committed to glycolysis [11]. During glycolysis,
glucose is converted to pyruvate which is either oxidized (glucose
oxidation) or converted to lactate (Fig. 1). When glycolysis is coupled
to glucose oxidation, pyruvate enters the mitochondria via the mito-
chondrial pyruvate carrier (MPC), is converted to acetyl CoA by pyru-
vate dehydrogenase (PDH), and enters the tricarboxylic acid (TCA)
cycle, eventually resulting in the production of 31 ATP per molecule of
glucose metabolized [12–16]. When pyruvate does not enter glucose
oxidation, it is converted to lactate by lactate dehydrogenase. One of
the reasons this step is important is because it converts NADH back to
NAD+ so that it is available for glycolysis to continue. This occurs either
under anaerobic conditions or whenmitochondrial oxidation of the py-
ruvate is inhibited. If glucose is converted to 2 lactate molecules, then 2
ATP are produced from each glucose that passes through glycolysis.
Glucose oxidation is primarily regulated via the activity of PDH
(Fig. 1). PDH is part of a complex that also contains PDH kinase (PDK)
and PDHphosphatase (PDP) [17–19]. PDH is regulated by phosphoryla-
tion and by the levels of its products and substrates [17–19]. PDK in-
hibits PDH by phosphorylating it and PDP relieves this inhibition by
dephosphorylating PDH [17,20]. The activity of PDK is increased by ace-
tyl CoA and NADH [17,20]. The ratio of both NADH/NAD+ and acetyl
CoA/CoA regulates the activity of PDH, with higher values resulting in
lower PDH activity [17,20,21]. In addition, PDH activity is increased by
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PDP activity (which can occur as a result of increasedmitochondrial cal-
cium concentrations due to catecholamine stimulation and increased
cardiac workload) [22–24].
2.2. Fatty acid metabolism
Fatty acid β-oxidation is the process by which fatty acids are broken
down to produce ATP. Fatty acids primarily cross the cell membrane via
fatty acid protein transporters, which include fatty acid translocase
(FAT/CD36), plasma membrane bound fatty acid binding protein
(FABPpm), and tissue speciﬁc fatty acid transport proteins (FATP)
[25–28]. Fatty acyl CoA synthetase (FACS) then adds a CoA group to
the fatty acid (Fig. 1). In a series of steps necessary for long chain CoAs
to enter the mitochondria the long chain acyl CoA is converted to long
chain acylcarnitine by carnitine palmitoyltransferase 1 (CPT1), follow-
ing which carnitine acylcarnitine translocase (CAT) transports the
fatty acid across the innermitochondrial membrane, and CPT2 converts
the acylcarnitine back to acyl CoA. The long chain acyl CoA can then
enter fatty acid β-oxidation. One acetyl CoA is produced from each
cycle through the pathway as well as NADH and FADH2. The NADH
and FADH2 produced by both fatty acid β-oxidation and the TCA cycle
utilization of the acetyl CoA are used by the electron transport chain
to produce ATP.
2.3. Randle cycle
Fatty acid and glucose metabolism can regulate each other by a
process called the glucose/fatty acid cycle, or the Randle Cycle [29].
The acetyl CoA and NADH produced by fatty acid oxidation can inhibit
pyruvate dehydrogenase (Fig. 1) [23]. In addition, citrate inhibits
PFK1 and by increasing glucose-6-phosphate levels indirectly inhibits
hexokinase activity [30,31]. The acetyl CoA produced by PDH inhibits
the fatty acid oxidation enzyme 3-ketoacyl CoA thiolase [23]. In addi-
tion, the NADH produced during glucose oxidation inhibits the fatty
acid oxidation enzymes 3-hydroxyacyl CoA dehydrogenase and acyl
CoA dehydrogenase [23]. Acetyl CoA can also be converted to malonyl
CoA by acetyl CoA carboxylase (ACC), which inhibits fatty acid oxida-
tion via malonyl CoA inhibition of CPT1 [3,11,31,32].
The inhibition of glucose oxidation due to high fatty acid oxidation
rates is much more dramatic than the degree of glycolysis inhibitionT
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Fig. 1. Glucose and fatty acid metabolic pathways in the heart. In general, in the failing[2]. This increases the uncoupling of glycolysis from glucose oxidation,
which can lead to intracellular acidosis due to the increased levels of
lactate and protons produced [23,33]. Clearance of these protons can
also result in the accumulation of calcium and sodium, requiring ATP
expenditure to maintain these intracellular ion levels within a normal
range [2].2.4. Cardiac energy metabolism and efﬁciency
Cardiac efﬁciency is a measurement of the amount of oxygen re-
quired for a given amount of cardiac work. It can be deﬁned as the
amount of work produced by the heart per amount of O2 consumed
[23]. Since O2 is required formitochondrial oxidativemetabolism, alter-
ations in energy metabolism can affect cardiac efﬁciency. Compared to
glucose, fatty acids are an inefﬁcient energy substrate. The full oxidation
of 1 glucose molecule requires 6 O2 and produces 31 ATP. Palmitate ox-
idation requires 23 O2 but only produces 105 ATP. However, the actual
decrease in cardiac efﬁciency due to elevated fatty acid oxidation rates
is actually much higher than expected due to calculated ATP/O2 ratios
(up to 30% instead of 10%), suggesting that other mechanisms are also
involved in fatty acids reducing cardiac efﬁciency [2]. One of these
mechanisms includes fatty acid inhibition of glucose oxidation, a more
efﬁcient metabolic pathway (see Randle Cycle section). Fatty acids
also inhibit adenine nucleotide transferase (ANT) thereby inhibiting
the transport of ATP from the mitochondrial matrix to the outside the
mitochondria [2]. A third mechanism involves fatty acid activation of
sarcolemmal calcium channels. More ATP has to be used to keep the cy-
tosolic calcium levels at normal levels instead of being used for work
[34]. Further, futile cycles may also contribute to fatty acid induced car-
diac inefﬁciency. These futile cycles include uncoupling proteins (UCP)
and the cycling of fatty acids between triacylglycerol and acyl CoAmoi-
eties (Fig. 2) [2]. UCP2 and UCP3 are believed to uncouple oxidative
phosphorylation by dissipating the mitochondrial intermembrane pro-
ton gradient created by the electron transport chain [23,35]. In the fail-
ing heart, increases in circulating fatty acid levels correlate positively
with increases in UCP2 and UCP3 protein expression [36]. In addition,
UCP3 may reduce cardiac efﬁciency by transporting fatty acid anions
out of the mitochondria [23,37].
Cycling of fatty acids between intracellular triacylglycerol stores and
acyl CoA moieties is another cause of reduced cardiac efﬁciency (Fig. 2)
[2]. The esteriﬁcation of a fatty acid to a fatty acyl CoA requires two highGlucose
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ther undergo fatty acid oxidation or be stored as triacylglycerol. To un-
dergo fatty acid β-oxidation, the fatty acids must be liberated from
triacylglycerol, a processwhichmay contribute to the fatty acid induced
cardiac inefﬁciency.3. Cardiac energy metabolism in heart failure
The changes in cardiac metabolism during heart failure are com-
plex and depend on the stage of heart failure [2]. The nature of these
cardiac metabolic changes are further complicated by the fact that
heart failure can have many causes including pressure overload, vol-
ume overload, myocardial infarction, and genetic alterations [38,39].
During the progression of heart failure, myocardial ATP content can
decrease, and can drop to 60–70% of normal levels [2,40–43]. There
is also a dramatic drop in phosphocreatine levels in the failing heart
[42–44]. This is accompanied by a decrease inmitochondrial oxidative
metabolism and a compensatory increase in glucose uptake and gly-
colysis [2,40–43,45–47]. This rise in glycolysis is an adaptation to the
reduced oxidative metabolism. However, because this rise in glycoly-
sis occurs independent of glucose oxidation, proton and lactate pro-
duction also increases in the heart [2,48]. This increase in lactate and
proton production has the potential to be detrimental to the heart.
This uncoupling of glycolysis and glucose oxidation is even further ex-
acerbated by a rise in circulating fatty acids that can occur in heart
failure.
During heart failure cardiac energy metabolism appears to revert
back toward a fetal metabolic phenotype. The decrease in fatty acid
oxidation and rise in glycolysis observed in pressure overloadH+
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Fig. 2. Fatty acid-induced futile cycling in the heart. Fatty acids can decrease cardiac efﬁciency th
triacylglycerol uses ATP. Efﬁciency of ATP production can also potentially be reduced by uncoup
Mitochondrial thioesterase cleavage of long chain acyl CoA and the transport of fatty acid outhypertrophied hearts are accompanied by changes in expression and
activity of metabolic enzymes involved in these pathways [49–56].
The expression of peroxisome proliferator activated receptor α (PPARα)
and peroxisome proliferator activated receptor gamma coactivator 1 α
(PGC-1α), enzymes that regulate mitochondrial biogenesis and fatty
acid oxidation enzyme expression, are decreased in the hypertrophied
heart [57]. In addition, GLUT1 protein expression and enolase activity,
an enzyme in glycolysis, are increased in the hypertrophied heart
[58,59].
The exact cardiac energy metabolic alterations are not completely
consistent between models of heart failure and stages of heart failure.
In hearts with preserved ejection fraction despite being subjected to
pressure overload and infarcted hearts with heart failure fatty acid
oxidation gene expression is reduced [46,60]. In addition, in heart
failure caused by aortic banding fatty acid oxidation rates are reduced
[61]. In severe end stage heart failure caused by aortic banding an
overall depression of oxidative metabolism occurs [62,63]. In con-
trast, in severe heart failure caused by rapid ventricular pacing fatty
acid β-oxidation rates are reduced and glucose oxidation rates are el-
evated [47,64,65]. It has also been reported that fatty acid uptake and
oxidation is reduced and glucose uptake is increased in human hearts
with dilated cardiomyopathy [66].4. Treating heart failure by targeting mitochondrial oxidative
metabolism
A considerable amount of emerging experimental and clinical data
has shown that targeting cardiac energy metabolism can be beneﬁcial
in treating heart failure. The strategy of decreasing fatty aciddrial 
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ling themitochondrial proton gradient due to increased uncoupling protein (UCP) activity.
of the mitochondria also results in a futile cycling that increases ATP use.
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promising [23]. These targets include modifying fatty acid
β-oxidation, decreasing levels of circulating fatty acids, and stimulat-
ing PDH (Fig. 3). Potential therapeutic strategies are likely to vary
depending on the stage of heart failure, since the function of mito-
chondria is reduced in severe heart failure, which indicates that re-
ducing fatty acid oxidation could be deleterious due to a decrease in
the limited capacity to generate ATP [3,23]. In addition, it has been
suggested that reducing circulating fatty acids can reduce cardiac
function in the failing heart, indicating the importance of fatty acid
as a substrate [67]. It may therefore be more beneﬁcial in severe
heart failure to target an overall increase in oxidative metabolism,
such as increasing glucose oxidation as opposed to inhibiting fatty
acid oxidation. This supports the hypothesis that the failing heart
has low energy levels and any increase in energy supply would be
beneﬁcial. However, numerous other experimental and clinical stud-
ies have shown that inhibiting fatty acid oxidation can improve the
function and efﬁciency of the failing heart. Discrepancies in reported
results may be explained by studies being conducted at different
stages of heart failure and/or causes of heart failure.4.1. β-Adrenoceptor antagonists
β-Adrenoceptor antagonists are an important therapy used to treat
heart failure. The negative inotropic and chronotropic effects of β-
adrenoceptor antagonists reduce cardiacworkload and increase oxygen
sparing, which are themajor reasons these drugs are used to treat heart
failure [23]. However, inhibition of CPT1 activity, increased glucose ox-
idation, and increased efﬁciency of oxygen utilization for ATP produc-
tion may also be partially responsible for the beneﬁcial effect of
β-adrenoceptor antagonists in heart failure [68,69]. β-Adrenoceptor an-
tagonists improve left ventricle (LV) function without changing oxygen
consumption, which indicates increased cardiac efﬁciency [23,70,71].
Carvedilol also reduces myocardial fatty acid uptake in heart failure pa-
tients [72]. In addition, β-adrenoceptor antagonists can decrease circu-
lating fatty acid levels by reducing catecholamine induced lipolysis atNADH 
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Fig. 3. Metabolic targets for the treatment of heart failure. β-Adrenoreceptor antagonists and P
(CPT1) inhibitors decrease fatty acid β-oxidation and increase glucose oxidation by decreasing
also decreases CPT1 activity by increasingmalonyl CoA inhibition of CPT1. Trimetazidine and ran
oxidation by inhibiting pyruvate dehydrogenase kinase (PDK) activity and thereby stimulatingthe level of adipose tissue [23]. However, metoprolol improves cardiac
function despite not reducing circulating fatty acid levels [32].4.2. PPAR agonists
Drugs that target the PPAR family of transcription factorsmay be ben-
eﬁcial in heart failure. PPARβ/δ is a transcription factor that regulates the
expression of genes involved in fatty acid metabolism. Some of these
genes include FACS, CPT1, LCAD, andMCAD [73–75]. By increasing the ex-
pression of these genes PPARβ/δ can increase fatty acid oxidation and
overall fatty acid utilization [73,75–77]. In cardiomyocytes PPARβ/δ
have been reported to prevent hypertrophy induced down-regulation of
fatty acid β-oxidation and expression of genes involved in fatty acid
metabolism [76,77]. In addition, PPARβ/δ regulates expression of proteins
involved in glucose metabolism. These genes include GLUT1, GLUT4,
PFK1, and hexokinase 2 [78]. Furthermore, PPARβ/δ speciﬁc cardiac
overexpression increases cardiac glucose oxidation rates [78]. Together,
these results suggest that therapeutically increasing PPARβ/δ activity
may be beneﬁcial in the setting of heart failure by at least partially
preventing the decrease in oxidativemetabolismobserved in heart failure
[23].
The thiazolidinedione (TZD) class of drugs targets PPARγ. TZDs de-
crease circulating fatty acids and triacylglycerol levels, increasemyocar-
dial lactate uptake and oxidation, and increase myocardial glucose
oxidation [79–81]. These results suggest that TZDs improve cardiac efﬁ-
ciency. However, there is evidence that increasing PPARγ activity could
also be detrimental to heart function in heart failure patients. Safety
concerns have been raised by clinical trials testing TZD therapy for
heart failure in diabetics. The exacerbated heart failure in diabetic pa-
tients has been suggested to be due to vascular permeability and ﬂuid
retention [82]. In addition, the Prospective Pioglitazone Clinical Trial
in Macrovascular Events (PROactive) Study reported that treatment
with the PPARγ agonist pioglitazone increase heart failure incidence
[83]. Meta-analysis suggest that rosiglitazone also increases the risk of
myocardial infarction but not overall mortality due to cardiovascular
events [84,85]. The ongoing Rosiglitazone Evaluated for CardiacGlucose
GLUT4
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PAR agonists decrease the level of circulating fatty acids. Carnitine palmitoyltransferase I
fatty acid transport into the mitochondria. Malonyl CoA decarboxylase (MCD) inhibition
olazine can directly inhibit fatty acidβ-oxidation. Dichloroacetate (DCA) increases glucose
pyruvate dehydrogenase (PDH).
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also reported that rosiglitazone increases the risk of heart failure [86].
Fibrates are a group of PPARα agonist drugs. They are believed to
work by lowering circulating fatty acid levels via increasing extracardiac
fatty acid oxidation [87,88]. The decreased fatty acid supply would re-
sult in decreased heart fatty acid oxidation. It has been reported that
the PPAR alpha agonists protect against ischemia/reperfusion injury
[89]. However, clinical trials have reported mixed results for ﬁbrate
treatment. Fenoﬁbrate was beneﬁcial in the Helsinki Heart Study and
the VA-HIT trial but in the FIELD study there was no reduction in coro-
nary heart disease mortality [90–92].
4.3. Fatty acid uptake into mitochondria
The rate limiting enzyme for fatty acid β-oxidation, and thus a po-
tential drug target for regulating mitochondrial fatty acid uptake, is
CPT1 (Fig. 3). Drugs targeting CPT1 include etomoxir, an irreversible
CPT1 inhibitor [93], and perhexiline. In diabetic rat hearts, etomoxir in-
creases glucose oxidation and improves cardiac function [94,95].
Etomoxir also improves the ventricular function of hearts subjected to
pressure overload [96]. It has been suggested that etomoxir is also ben-
eﬁcial in heart failure by increasing sarcoplasmic reticulum calcium up-
take in hypertrophied hearts [97]. The results of clinical trials are less
clear. While one clinical trial found that etomoxir improves the clinical
status of heart patients and heart function [98], another clinical trial had
to end early due to high liver transaminase levels despite evidence of an
increase in exercise time [99]. Perhexiline is a CPT1 inhibitor that in-
hibits the cardiac, but not hepatic, isoform of CPT1. In chronic heart fail-
ure, perhexiline improves VO2 max, left ventricular ejection fraction,
and overall myocardial energetics [100,101]. In addition, the beneﬁcial
effects of β-adrenoceptor antagonists may be partially due to inhibition
of CPT1 activity, increased glucose oxidation, and increased efﬁciency of
oxygen utilization for ATP production [68,69]. Therefore, targeting CPT1
may be useful in treatment of heart failure.
4.4. Malonyl-CoA decarboxylase inhibitors
Malonyl CoA decarboxylase (MCD) inhibition leads to a rise in car-
diac malonyl CoA levels which inhibit CPT1, thereby reducing mito-
chondrial fatty acid uptake. MCD inhibition results in a decrease in
cardiac fatty acid oxidation, a rise in cardiac glucose oxidation, and
an increase in insulin sensitivity [102–106]. It is has not been tested
yet whether MCD inhibition is beneﬁcial in heart failure but since
there are beneﬁcial effects of direct inhibition of CPT1, this indirect
method of CPT1 inhibition may also be beneﬁcial in heart failure.
4.5. Mitochondrial fatty acid oxidation inhibition
The enzymes involved in mitochondrial fatty acid β-oxidation
could also be targeted for the treatment of heart failure. Two drugs
that target fatty acid β-oxidation include trimetazidine, a competitive
inhibitor of long chain 3-ketoacyl-CoA thiolase (KAT), and ranolazine
[107,108]. Although it has been reported that trimetazidine does not
inhibit 3-KAT activity in rat hearts [109], at relevant concentrations
of the substrate for 3-KAT, trimetazidine is indeed a potent inhibitor
of 3-KAT [108]. In hypertrophied hearts, trimetazidine reduces glycol-
ysis and proton production, but does not affect fatty acid oxidation
[110]. In heart failure patients, trimetazidine also further increases
the effectiveness of treatment regimens, improving NYHA functional
class, LV ejection fraction and end-diastolic function [111,112]. In id-
iopathic heart failure patients, not only does trimetazidine improve
cardiac function, but it also improves whole body insulin sensitivity
[113].
Although ranolazine is marketed as a slow sodium current inhibitor,
at clinically relevant concentrations, ranolazine is also a partial inhibitor
of fatty acid oxidation [114–117]. Recently, it has also been suggestedthat a reduction in myoﬁlament sensitivity is involved in ranolazine
beneﬁt in diastolic heart failure [118]. Ranolazine is currently being
clinically used as an anti-ischemic agent. Ranolazine treatment does re-
sult in increased PDH activity and glucose oxidation [114–117]. Not sur-
prisingly, ranolazine is also known to increase the coupling of glycolysis
to glucose oxidation [115,116]. Interesting, ranolazine also inhibits the
electron transport chain in damaged or uncoupled mitochondria, pre-
venting ATPwasting due to futile cycling [119]. It is thereforemore like-
ly that inhibition of fatty acid oxidation and subsequent increased
glycolysis glucose oxidation coupling is responsible for the beneﬁcial ef-
fects of ranolazine in heart failure. Improved cardiac function has been
reported in a canine model upon ranolazine administration [119,120].
Threemonths of ranolazine treatment prevented further LV remodeling
and reduction in contractile function [121]. The efﬁcacy of ranolazine in
heart failure patients with preserved ejection fraction is currently now
being examined in a small clinical study [122].
4.6. Pyruvate dehydrogenase kinase inhibitors
Directly increasing glucose oxidation is another potential strategy to
treat heart failure. Dichloroacetate (DCA) increases PDH activity by
inhibiting PDK, thereby increasing glucose oxidation (Fig. 3). This
mechanism is responsible for the cardioprotection observed with DCA
treatment [48,123]. In a study conducted in Dahl Sensitive rats DCA re-
duced LV hypertrophy progression to heart failure [45]. Other PDK in-
hibitors include SDZ048-619 and AZD7545, a selective inhibitor of
PDK2. In the diabetic Zucker rat it has been shown that SDZ048-619 in-
creases PDH activity in the liver, kidney, skeletal, and cardiac muscle
[124,125]. AZD7545 increases PDH activity in the liver and, to a lesser
extent, in skeletal and cardiac muscle [126]. While more work needs
to be done to conﬁrm that SDZ048-619 and AZD7545 increase cardiac
glucose oxidation, these drugs are promising future agents for both
therapeutic use and for scientiﬁc research.
4.7. Medium chain fatty acids
Medium chain fatty acids (MCFAs) are regulated in a different man-
ner than long chain fatty acids [127]. MCFAs can cross the sarcolemmal
and mitochondrial membranes independent of protein transport,
bypassing any regulatory effects of CPT1 in their transport into mito-
chondria and/or oxidation in mitochondria. MCFAs are also believed
to be preferentially used in fatty acid oxidation, as opposed to being
stored as triacylglycerol. Because the cycling between triacylglycerol
and fatty acid CoAs is an ATP consuming process [128], the reduction
in futile cycling could potentially be useful in conditions of impaired
ability to produce ATP, such as heart failure. MCFAs have not been ex-
amined in the failing heart. In the spontaneously hypertensive rat,
MCFA dietary supplementation improves cardiac function, reduces car-
diac hypertrophy, improves elevated insulin levels, and blocks progres-
sion of LV diastolic pressure [129–131]. Because MCFAs prevent both
the reduction inMCAD expression and increase in PFK1 protein expres-
sion [130] in cardiac hypertrophy it has been suggested thatMCFAsmay
prevent the reduced oxidative metabolism and increased glycolysis ob-
served in the hypertrophied heart [23].
5. Limitation of metabolic modulation for treating heart failure
While regulating energy metabolism in the failing heart appears to
be therapeutically beneﬁcial in the treatment of heart failure, some as-
pects need to be considered to prevent potential problems with such a
strategy. One such problem is that if fatty acids donot undergo fatty acid
β-oxidation they may be used in the production of triacylglycerol,
diacylglycerol, and ceramides [2,132]. The accumulation of these lipid
metabolites has been proposed to cause “cardiac lipotoxicity”, which
may induce a number of cardiac problems including impaired diastolic
ﬁlling, cardiomyocyte cell death, LV chamber enlargement, and ﬁbrosis
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could also cause such problems since, via the reverse Randle cycle,
fatty acid β-oxidation would also be inhibited, which could lead to
triacylglycerol accumulation [140]. However, there is evidence that
triacylglycerol accumulation is not associated with cardiac dysfunction
suggesting that its accumulation is not involved in “cardiac lipotoxicity”
[141,142]. In fact, hearts from mice in which fatty acid oxidation is ele-
vated due to cardiac speciﬁc deletion of ACC2 are protected against
myocardial hypertrophy [143]. This perhaps suggests that chronic
upregulation of fatty acid oxidation is protective because it prevents in-
creases in lipid metabolites suggested to be involved in “cardiac
lipotoxicity.”
6. Conclusions
Mitochondrial oxidative metabolism is a promising target for the
treatment of heart failure. An effective strategy appears to be inhibi-
tion of fatty acid oxidation and increasing the coupling of glycolysis
to glucose oxidation. In order to achieve this, targets could include
CPT1, fatty acid β-oxidation enzymes, and PDK. Modulating energy
metabolism has the potential to improve cardiac function by improv-
ing the efﬁciency with which the heart utilizes ATP. This could lessen
the energetic deﬁciency in ATP that can occur as the heart fails. Fur-
ther, clinical and experimental studies are required to conﬁrm the ef-
ﬁcacy of targeting many of these metabolic proteins as an approach to
treating heart failure.
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